Intraperitoneal versus intravenous cisplatin in combination with intravenous cyclophosphamide and epidoxorubicin in optimally cytoreduced advanced epithelial ovarian cancer: A randomized trial of the Gruppo Oncologico Nord-Ovest

Gynecologic Oncology

Volumn 76, Issue 2, 2000, Pages 157-162

  Gadducci, Angiolo ^d   Carnino, Flavio ^a   Chiara, Silvana ^b   Brunetti, Isa ^c   Tanganelli, Lucia ^c   Romanini, Antonella ^c   Bruzzone, Milena ^b   Conte, Pier Franco ^c  

^a S ANNA HOSPITAL   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF PISA   (Italy)

^d NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; EPIRUBICIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CARDIOTOXICITY; DRUG EFFECT; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL;

EID: 0033958018     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5677     Document Type: Article

References (23)

1. Dedrick R L. Theoretical and experimental bases of intraperitoneal chemotherapy. Semin Oncol. 12:1985;1-6.
2. Markman M, Reichman B, Hakes T, Curtin J, Jones W, Lewis J L Jr, Barakat R, Rubin S, Mychalczak B, Saigo P, Almadrones L, Hoskins W. Intraperitoneal chemotherapy in the management of ovarian cancer. Cancer. 71:1993;1565-1570.
3. Markman M. Intraperitoneal therapy of ovarian cancer. Semin Oncol. 25:1998;356-360.
4. Howell S B, Zimm S, Markman M, Abramson I S, Cleary S, Lucas W E, Weiss R J. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol. 5:1987;1607-1612.
5. Piver M S, Lele S B, Marchetti D L, Baker T L, Emrich L J, Hartman A B. Surgically documented response to intraperitoneal cisplatin, cytarabine, and bleomycin after intravenous cisplatin-based chemotherapy in advanced ovarian adenocarcinoma. J Clin Oncol. 6:1988;1679-1684.
6. Reichman B, Markman M, Hakes T, Hoskins W, Rubin S, Jones W, Almadrones L, Ochoa M Jr, Chapman D, Saigo P, Lewis J L Jr. Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol. 7:1989;1327-1332.
7. McClay E F, Howell S B. A review: intraperitoneal cisplatin in the management of patients with ovarian cancer. Gynecol Oncol. 36:1990;1-6.
8. Markman M, Hakes T, Reichman B, Hoskins W, Rubin S, Jones W, Almadrones L, Jordan E L Jr, Eriksson J, Lewis J L Jr. Intraperitoneal cisplatin and cytarabine in the treatment of refractory or recurrent ovarian carcinoma. J Clin Oncol. 9:1991;204-210.
9. Kirmani S, Lucas W E, Kim S, Goel R, Mcvey L, Morris J, Howell S B. A Phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma. J Clin Oncol. 9:1991;649-657.
10. Alberts D S, Liu P Y, Hannigan E V, O'Toole R, Williams S D, Young J A, Franklin E W, Clarke-Pearson D L, Malviya V K, DuBeshter B, Adelson M D, Hoskins W J. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med. 335:1996;1950-1955.
11. Markman M, Bundy B, Benda J, Alberts D, Wadler S, Fowler J, Clarke-Pearson D, Carson L F. Randomized phase 3 study of intravenous (IV) cisplatin (CIS)/paclitaxel (PAC) versus moderately high dose IV carboplatin (CARB) followed by IV PAC and intraperitoneal (IP) CIS in optimal residual ovarian cancer (OC): an Intergroup trial (GOG, SWOG, ECOG). Proc Am Soc Clin Oncol. 17:1998;361.
12. Levin L, Hryniuk W M. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma. J Clin Oncol. 5:1987;756-767.
13. Kaye S B, Paul J, Cassidy J, Lewis C R, Duncan I D, Gordon H K, Kitchener H C, Cruickshank D J, Atkinson R J, Soukop M, Rankin E M, Davis J A, Reed N S, Crawford S M, MacLean A, Parkin D, Sarkar T K, Kennedy J, Symonds R P. Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer. Scottish Gynecologic Cancer Trial Group. J Clin Oncol. 14:1996;2113-2119.
14. McGuire W P, Hoskins W J, Brady M F, Homesley H D, Creasman W T, Berman M L, Ball H, Berek J S, Woodward J. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 13:1995;1589-1599.
15. Colombo N, Pittelli M R, Parma G, Marzola M, Torri W, Mangioni C. Cisplatin (P) dose intensity in advanced ovarian cancer (AOC): a randomized study of conventional dose (DC) vs dose-intense (DI) cisplatin monochemotherapy. Proc Am Soc Clin Oncol. 12:1993;255.
16. Conte P F, Bruzzone M, Carnino F, Gadducci A, Algeri R, Bellini A, Boccardo F, Brunetti I, Catsafados E, Chiara S, Foglia G, Gallo L, Iskra L, Mammoliti S, Parodi G, Ragni N, Rosso R, Rugiati S, Rubagotti A. High-dose versus low-dose cisplatin in combination with cyclophosphamide and epidoxorubicin in suboptimal ovarian cancer: a randomized study of the Gruppo Oncologico Nord-Ovest. J Clin Oncol. 14:1996;351-356.
17. Los G, Mutsaers P HA, van der Vijgh W JF, Baldew G S, de Graaf P W, McVie J G. Direct diffusion of cisdiamminodichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res. 49:1989;3380-3384.
18. Bruzzone M, Rubagotti A, Gadducci A, Catsafados E, Foglia G, Brunetti I, Giannessi P G, Carnino F, Iskra L, Rosso R, Martoni A, Pannuti F, De Lisi V, Maltoni R, Ridolfi R, Mammoliti S, Gallo L, Boccardo F, Ragni N, Conte P F. Intraperitoneal carboplatin with or without interferon-a in advanced ovarian cancer patients with minimal residual disease at second look: a prospective randomized trial of 111 patients. Gynecol Oncol. 65:1997;499-505.
19. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
20. Stuart G, Bertelsen K, Mangioni C, Trope C, James K, Cassidy J, Kaye S, Timmers P, Roy J A, Piccart M J. Updated analysis shows a highly significant improved overall survival (OS) for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTCGCCG, NOCOVA, NCIC CTG and Scottish Intergroup trial. Proc Am Soc Clin Oncol. 17:1998;361.
21. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis J L Jr, Rubin S, Curtin J, Barakat R, Phillips M, Horowitz L, Almadrones L, Hoskins W. Phase I intraperitoneal Taxol: a Gynecologic Oncology Group study. J Clin Oncol. 10:1992;1485-1491.
22. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology Group pilot study. J Clin Oncol. 13:1995;2961-2967.
23. Markman M, Brady M F, Spirtos N M, Hanjani P, Rubin S C. Phase II trial of intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic Oncology Group Study. J Clin Oncol. 16:1998;2620-2624.